title: Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
abstract: Inhibition of urokinase has been shown to slow tumor growth and metastasis. To utilize structure-based drug design, human urokinase was re-engineered to provide a more optimal crystal form. The redesigned protein consists of residues Ile(16)-Lys(243) (in the chymotrypsin numbering system; for the urokinase numbering system it is Ile(159)-Lys(404)) and two point mutations, C122A and N145Q (C279A and N302Q). The protein yields crystals that diffract to ultra-high resolution at a synchrotron source. The native structure has been refined to 1.5 A resolution. This new crystal form contains an accessible active site that facilitates compound soaking, which was used to determine the co-crystal structures of urokinase in complex with the small molecule inhibitors amiloride, 4-iodo-benzo(b)thiophene-2-carboxamidine and phenylguanidine at 2. 0-2.2 A resolution. All three inhibitors bind at the primary binding pocket of urokinase. The structures of amiloride and 4-iodo-benzo(b)thiophene-2-carboxamidine also reveal that each of their halogen atoms are bound at a novel structural subsite adjacent to the primary binding pocket. This site consists of residues Gly(218), Ser(146), and Cys(191)-Cys(220) and the side chain of Lys(143). This pocket could be utilized in future drug design efforts. Crystal structures of these three inhibitors in complex with urokinase reveal strategies for the design of more potent nonpeptidic urokinase inhibitors.
authors.affiliation: Department of Structural Biology, Abbott Laboratories, Abbott Park, Illinois 60064, USA. vicki.nienaber@abbott.com
authors.forename: V
authors.initials: V
authors.lastname: Nienaber
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: D
authors.initials: D
authors.lastname: Davidson
authors.forename: J
authors.initials: J
authors.lastname: Henkin
mesh_terms: D000584:Amiloride / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D003460:Crystallization; D015195:Drug Design; D006146:Guanidines / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008970:Molecular Weight; D015202:Protein Engineering; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry*
chemical_list: D006146:Guanidines; C026943:phenylguanidine; D000584:Amiloride; D014568:Urokinase-Type Plasminogen Activator